Fetal growth restriction is associated with accelerated telomere shortening and increased expression of cell senescence markers in the placenta

A hallmark of fetal growth restriction (FGR) is restricted placental development and insufficient nutrient supply to the fetus. It has previously been shown that activity levels of telomerase, the enzyme responsible for completing replication of telomeric DNA during cell division, is suppressed in FGR placenta samples as compared to control placenta samples from donors of the same gestational age. Here we examine whether telomere length maintenance is also compromised in FGR placenta samples. Southern analysis of telomere length for placenta and cord blood samples from 32 FGR and 36 control donors, ranging in gestational age from 37 to 40 weeks, revealed significantly shorter telomeres (P<or=0.001) in FGR placenta samples, but not cord blood samples. Furthermore, analysis of telomerase extracts, RNA and DNA placental samples from donors with and without idiopathic FGR confirmed a direct association between suppression of telomerase activity and reduced telomere length in FGR placenta. In addition, expression levels of markers of telomere-induced senescence, p21, p16 and EF-1 alpha, were significantly elevated in FGR placenta samples (P<or=0.01). These observations support a direct affect of reduced telomerase activity levels on the placental pathology associated with FGR.

Screening for psychosis risk in primary mental health care services - Implementation, prevalence and recovery trajectories

OBJECTIVES

Early interventions improve outcomes for people at high risk of psychosis and are likely to be cost saving. This group tends to seek help for emotional problems - depression and anxiety - via primary care services, where early detection methods are poor. We sought to determine prevalence rates of high risk for psychosis in UK primary care mental health services and clinical outcomes following routinely delivered psychological therapies.

METHODS

We used a brief screen designed for settings with low base rates and significant time constraints to determine prevalence of high risk for psychosis in UK 'Talking Therapies' services. We examined socio-demographic characteristics, presenting problems and recovery trajectories for this group, compared with people not at risk of psychosis.

RESULTS

A 2-item screen selected for specificity yielded a prevalence rate of 3% in primary care mental health services. People at elevated risk of psychosis were younger and more likely to report at least one long-term physical condition. This group presented with higher levels of depression, anxiety and trauma symptoms at assessment and were less likely to have recovered at the end of treatment, compared to people not at risk.

CONCLUSIONS

Very brief screening tools can be implemented in busy health care settings. The 3% of referrals to UK primary care psychological therapies services at elevated risk of psychosis typically present with more severe symptoms and greater levels of comorbidity and may require augmented interventions to recover fully.